Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2010

View Archived Issues

Four-year COMBAT data detail benefits of Duodart in benign prostatic hyperplasia

Actelion discloses novel oxazolidinyl antibacterials

Cancer Research Technology claims novel Wnt signaling inhibitors

Resolvyx Pharmaceuticals claims novel compounds with antiinflammatory activity

Pfizer claims novel AMPA receptor agonists

Schering claims novel alpha2C-adrenoceptor modulators

Phase I/II results reported for GMI-1070 in sickle cell disease

Covalent irreversible HCV NS3 protease inhibitors disclosed by Avila Therapeutics

GI-5005 plus pegIFNalpha-2a/RBV shows clinical potential in chronic HCV patients

Endotis Pharma's synthetic oligosaccharide EP-80061 shows antitumor activity in animal models

Sanofi-aventis and Glenmark enter license agreement for chronic pain treatments

FDA issues complete response letter regarding Bristol-Myers Squibb's BLA for belatacept

Algeta and Bayer complete sample size re-estimation of ALSYMPCA trial of Alpharadin

Bicycle Therapeutics signs license agreement with EPFL in Switzerland

Labopharm and Angelini establish joint venture to commercialize Oleptro

IRX forms vaccine collaboration with Japan's National Cancer Research Center

UCB offers Q1 overview

Jak3 inhibitor R-348 prevents acute rejection and OAD in rodent model of transplantation

Clinical study, meta-analysis reveal intraocular pressure reductions with PF-4217329

Repros receives guidance from FDA regarding clinical hold status of Proellex

Avanir submits complete response to FDA approvable letter for Zenvia

BioCancell receives FDA approval to continue phase IIb bladder cancer trial

AlphaRx subsidiary and Pacific Orient form Pacific Orient BioPharma Group

Althea Technologies acquires Altus' assets and IP portfolio

Targacept and AstraZeneca amend agreement to expand TC-5619 development program

Phase III study of TDT-067 for onychomycosis has enrolled first patient

AG-011 ineffective in phase II ulcerative colitis study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...